Literature DB >> 33787322

Glycoursodeoxycholic Acid Ameliorates Atherosclerosis and Alters Gut Microbiota in Apolipoprotein E-Deficient Mice.

Kan Huang1,2, Chenshu Liu1,2, Meixiu Peng1,2, Qiao Su3, Ruiming Liu2, Zeling Guo4, Sifan Chen5, Zilun Li1,2, Guangqi Chang1,2.   

Abstract

Background Although glycoursodeoxycholic acid (GUDCA) has been associated with the improvement of metabolic disorders, its effect on atherosclerosis remains elusive. This study aimed to investigate the role of GUDCA in the development of atherosclerosis and its potential mechanisms. Methods and Results Human THP-1 macrophages were used to investigate the effect of GUDCA on oxidized low-density lipoprotein-induced foam cell formation in vitro. We found that GUDCA downregulated scavenger receptor A1 mRNA expression, reduced oxidized low-density lipoprotein uptake, and inhibited macrophage foam cell formation. In an in vivo study, apolipoprotein E-deficient mice were fed a Western diet for 10 weeks to induce atherosclerosis, and then were gavaged once daily with or without GUDCA for 18 weeks. Parameters of systemic metabolism and atherosclerosis were detected. We found that GUDCA improved cholesterol homeostasis and protected against atherosclerosis progression as evidenced by reduced plaque area along with lipid deposition, ameliorated local chronic inflammation, and elevated plaque stability. In addition, 16S rDNA sequencing showed that GUDCA administration partially normalized the Western diet-associated gut microbiota dysbiosis. Interestingly, the changes of bacterial genera (Alloprevotella, Parabacteroides, Turicibacter, and Alistipes) modulated by GUDCA were correlated with the plaque area in mice aortas. Conclusions Our study for the first time indicates that GUDCA attenuates the development of atherosclerosis, probably attributable to the inhibition of foam cell formation, maintenance of cholesterol homeostasis, and modulation of gut microbiota.

Entities:  

Keywords:  atherosclerosis; cholesterol homeostasis; foam cell; glycoursodeoxycholic acid; gut microbiota

Year:  2021        PMID: 33787322     DOI: 10.1161/JAHA.120.019820

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  3 in total

1.  Identification of Serum Metabolomics Characteristics in Patients with Stable Angina Pectoris Using UHPLC-QE-MS.

Authors:  Yufei Zhou; Chen Zhou; Gang Luo; Wei Ren; Li Dong; Junjie Liang; Linshen Mao; Mengnan Liu; Yanli Dong; Pan Liang; Sijin Yang
Journal:  Comput Math Methods Med       Date:  2022-05-16       Impact factor: 2.809

2.  Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.

Authors:  Zilun Li; Meixiu Peng; Pin Chen; Chenshu Liu; Ao Hu; Yixin Zhang; Jiangyun Peng; Jiang Liu; Yihui Li; Wenxue Li; Wei Zhu; Dongxian Guan; Yang Zhang; Hongyin Chen; Jiuzhou Li; Dongxiao Fan; Kan Huang; Fen Lin; Zefeng Zhang; Zeling Guo; Hengli Luo; Xi He; Yuanyuan Zhu; Linghua Li; Bingding Huang; Weikang Cai; Lei Gu; Yutong Lu; Kai Deng; Li Yan; Sifan Chen
Journal:  Cell Metab       Date:  2022-02-11       Impact factor: 27.287

3.  Gut microbiota-derived metabolites in inflammatory diseases based on targeted metabolomics.

Authors:  Hui Xu; Li-Bin Pan; Hang Yu; Pei Han; Jie Fu; Zheng-Wei Zhang; Jia-Chun Hu; Xin-Yu Yang; Adili Keranmu; Hao-Jian Zhang; Meng-Meng Bu; Jian-Dong Jiang; Yan Wang
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.